Iterum Therapeutics plc financials

ITRMF CIK 0001659323

Source: EDGAR filings · Built 2026-06-19T02:36:22Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Free Cash Flow -26.77M -39.34M -18.54M -15.90M -54.54M -81.95M
EBITDA -18.41M -45.72M -28.58M -22.43M -31.96M -101.87M
Working Capital 7.18M 12.08M 53.38M 70.33M -20.23M -25.27M
Net Debt 7.16M 5.93M -6.75M -14.99M 20.07M 15.95M
Operating Margin -275732.43%
Net Margin -278729.73%
Return on Equity (ROE) 607.06% 599.27% -158.70% -182.28% 102.86% 393.06%
Return on Assets (ROA) -55.55% -146.13% -66.49% -100.06% -158.59% -400.49%
Current Ratio 1.41× 1.89× 6.89× 6.43× 0.51× 0.32×
Debt-to-Equity -7.67× -1.88× 0.51× 0.25× -0.68× -0.79×
Effective Tax Rate -0.98% -1.62% -0.68% -0.78% -1.45% -0.43%
Cash Conversion Ratio 1.08× 1.02× 0.42× 0.17× 1.05× 0.79×
Accruals Ratio 0.04× 0.04× -0.39× -0.83× 0.08× -0.82×
SBC % of Revenue 5872.97%
CapEx Coverage -13385.00× -3025.38× -297.95× -259.70× -4957.09× -3413.42×
Free Cash Flow Per Share $-1.36 $-3.04 $-1.51 $-1.46 $-34.07 $-5.64

Income Statement

Concept FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Revenue from Contract with Customer, Excluding Assessed Tax 0 0 37.00K
Research and Development Expense 10.46M 39.99M 17.62M 10.71M 21.07M 90.77M
Operating Expenses 18.70M 47.47M 30.38M 24.54M 32.13M 102.06M
Operating Income (Loss) -18.70M -47.47M -30.38M -24.54M -32.13M -102.02M
Income Tax Expense (Benefit) 240.00K 613.00K 301.00K 705.00K 743.00K 444.00K
Net Income (Loss) Attributable to Parent -24.77M -38.37M -44.43M -91.56M -52.01M -103.13M
Earnings Per Share, Basic $-1.26 $-2.96 $-3.63 $-8.41 $-32.49
Weighted Average Number of Shares Outstanding, Basic 19.70M 12.96M 12.24M 10.89M 1.60M
Earnings Per Share, Diluted $-1.26 $-2.96 $-3.63 $-8.41 $-32.49
Weighted Average Number of Shares Outstanding, Diluted 19.70M 12.96M 12.24M 10.89M 1.60M

Balance Sheet

Concept FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Cash and Cash Equivalents, at Carrying Value 24.13M 6.07M 21.09M 27.45M 14.51M 4.80M
Assets, Current 24.79M 25.60M 62.44M 83.27M 21.47M 11.72M
Assets 44.59M 26.26M 66.83M 91.51M 32.79M 25.75M
Long-term Debt 31.22M 11.22M 12.71M
Liabilities, Current 17.61M 13.52M 9.06M 12.94M 41.70M 36.99M
Long-term Debt, Excluding Current Maturities 11.45M 10.09M 6.93M 22.46M 7.63M
Liabilities 48.68M 32.66M 38.83M 41.27M 83.35M 51.99M
Stockholders' Equity Attributable to Parent -4.08M -6.40M 28.00M 50.23M -50.56M -26.24M

Cash Flow Statement

Concept FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Net Cash Provided by (Used in) Operating Activities -26.77M -39.33M -18.47M -15.84M -54.53M -81.92M
Payments to Acquire Property, Plant, and Equipment 2.00K 13.00K 62.00K 61.00K 11.00K 24.00K
Net Cash Provided by (Used in) Investing Activities 18.21M 23.34M 13.96M -54.59M -11.00K 40.10M
Net Cash Provided by (Used in) Financing Activities 26.69M 1.03M -1.82M 83.13M 64.47M 2.06M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (ITRMF CIK 0001659323), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

PCYO

PURE CYCLE CORPORATION

AEIS

ADVANCED ENERGY INDUSTRIES INC

FSS

FEDERAL SIGNAL CORPORATION